Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

A Novel Mendelian Randomization Approach to Assess Treatment Outcomes in Patient Subgroups

FY 2021-22

Summary
Medical treatment decisions involve a balance of risks and benefits. While these risks and benefits are typically well defined for the general population, they are less clear for patient subgroups. For example, the effectiveness of cholesterol-lowering medications in reducing the risk of heart disease may vary across individuals of different ages and disease states. This information is important to know, as it can help healthcare providers tailor treatments to patients based on their clinical profiles. To identify subgroups of patients that are more or less likely to benefit from treatments, the Mendelian Randomization (MR) framework will be used. MR uses genetic variants related to a risk factor to determine how the risk factor is causally related to a disease. The use of genetic variants is key to the techniques ability to determine a causal effect rather than a simple association. This is because genetic variants are randomly allocated during conception and eliminate the involvement of common confounding variables such as environmental factors.We will be adapting the traditional MR framework to examine the relationship between risk factors and diseases for different biomarker levels using the UK Biobank database. For example, the effect of blood cholesterol levels on the risk of heart disease will be assessed for patients with different blood glucose levels. If cholesterol levels are not found to affect heart disease risk for patients with certain blood glucose levels, it could mean that it may actually be more beneficial for these individuals to withdraw from cholesterol-lowering therapy. This novel MR methodology will open a new paradigm of studies for determining treatment effects in patient subgroups and help tailor treatments to individual patients.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466836
Name
Man Alice P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Novel Mendelian Randomization Approach to Assess Treatment Outcomes in Patient Subgroups
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiometabolic Disease; Genetic Epidemiology; Mendelian Randomization; Precision Medicine
Abstract
Medical treatment decisions involve a balance of risks and benefits. While these risks and benefits are typically well defined for the general population, they are less clear for patient subgroups. For example, the effectiveness of cholesterol-lowering medications in reducing the risk of heart disease may vary across individuals of different ages and disease states. This information is important to know, as it can help healthcare providers tailor treatments to patients based on their clinical profiles. To identify subgroups of patients that are more or less likely to benefit from treatments, the Mendelian Randomization (MR) framework will be used. MR uses genetic variants related to a risk factor to determine how the risk factor is causally related to a disease. The use of genetic variants is key to the techniques ability to determine a causal effect rather than a simple association. This is because genetic variants are randomly allocated during conception and eliminate the involvement of common confounding variables such as environmental factors.We will be adapting the traditional MR framework to examine the relationship between risk factors and diseases for different biomarker levels using the UK Biobank database. For example, the effect of blood cholesterol levels on the risk of heart disease will be assessed for patients with different blood glucose levels. If cholesterol levels are not found to affect heart disease risk for patients with certain blood glucose levels, it could mean that it may actually be more beneficial for these individuals to withdraw from cholesterol-lowering therapy. This novel MR methodology will open a new paradigm of studies for determining treatment effects in patient subgroups and help tailor treatments to individual patients.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Man, Alice P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~